Novai

Executive Summary

Novai is a UK-based MedTech company founded in 2019 that is pioneering the use of its proprietary DARC (Detection of Apoptosing Retinal Cells) technology for the early detection of eye and brain diseases. By combining a novel biologic biomarker with an AI algorithm, the company aims to identify cellular-level disease activity before irreversible damage occurs, targeting glaucoma, age-related macular degeneration, and neurodegenerative conditions like Alzheimer's. The platform has the potential to transform diagnostics by enabling non-invasive, real-time monitoring of disease progression, benefiting patients, clinicians, and pharmaceutical partners in both ophthalmology and neurology. The company is currently in the pre-clinical stage, with significant validation and capital requirements ahead. While the technology is innovative and addresses substantial unmet medical needs—given the global burden of blindness and dementia—the path to commercialization involves regulatory hurdles and clinical trial execution. Novai’s success hinges on demonstrating clinical utility and securing partnerships or funding. If validated, the DARC platform could become a cornerstone in early diagnostic screening and drug development biomarkers, justifying a moderate conviction in its long-term potential.

Upcoming Catalysts (preview)

• Q1 2027CE Marking Application Submission for DARC Technology60% success
• Q4 2026First-in-Human Clinical Data Readout for Neurodegeneration Indication50% success
• Q2 2027Strategic Partnership with Pharmaceutical Company for Drug Development Use40% success